Suche
Mein Konto
Researchers identify gene expression that correlates with response to chemotherapy in medulloblastoma
An international team led by the Department of Neurosurgery at the University of Niigata has identified a new gene called Schlafen11 (SLFN11) whose expression correlates closely with response to chemotherapy in medulloblastoma, a highly malignant brain tumor that affects children, adolescents and young adults. Omics eBook Compilation of the top interviews, articles and news from the last year. Download a free copy The team led by Dr. Manabu Natsumeda first noted that SLFN11 is highly expressed in almost all cases of WNT-activated medulloblastomas, the molecular subgroup with the best prognosis. Further studies with medulloblastoma cell lines showed that genetic manipulation of SLFN11 leads to drastic...
Researchers identify gene expression that correlates with response to chemotherapy in medulloblastoma
An international team led by the Department of Neurosurgery at the University of Niigata has identified a new gene called Schlafen11 (SLFN11) whose expression correlates closely with response to chemotherapy in medulloblastoma, a highly malignant brain tumor that affects children, adolescents and young adults.
Omics eBook
Compilation of the top interviews, articles and news from the last year. Download a free copy
The team around Dr. Manabu Natsumeda first noted that SLFN11 is highly expressed in almost all cases of WNT-activated medulloblastomas, the molecular subgroup with the best prognosis. Further studies with medulloblastoma cell lines showed that genetic manipulation of SLFN11 led to dramatic changes in response to cisplatin, a key drug used to treat this deadly tumor. “Some cases of medulloblastoma respond better to treatment than others, but we didn’t know why.
We can now better predict which cases will respond to chemotherapy. "We even found that by using another drug called HDAC inhibitors, we can increase SLFN11 levels in tumors and make them more sensitive to cisplatin," explains Dr. Natsumeda. The results of the study were published online in the journal Neuro-Oncology on October 23, 2022.
Source:
Reference:
Nakata, S., et al. (2022) Epigenetic upregulation of Schlafen11 renders WNT- and SHH-activated medulloblastomas sensitive to cisplatin. Neuro-oncology. doi.org/10.1093/neuonc/noac243.
.